Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial ...
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to Eli Lilly’s (LLY) tirzepatide. Share price reaction ...
Denmark-headquartered Novo Nordisk, a leading global healthcare company founded in 1923 to drive change to defeat serious chronic diseases built upon our heritage in diabetes, announced headline ...
REDEFINE 1 - a 68-week efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or ...
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial ...
The phase III REDEFINE 2 trial, involving approximately 1,200 participants with a BMI of 27 or more, provided valuable insights into CagriSema's potential. This study employed a flexible dosing ...
Viyaara Realty, a premier Mumbai-based real estate developer, dedicated to creating exceptional living spaces is set to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback